Anthony Petrone
Stock Analyst at Mizuho
(3.70)
# 686
Out of 5,182 analysts
217
Total ratings
46.88%
Success rate
7.18%
Average return
Main Sectors:
Stocks Rated by Anthony Petrone
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MMED Minimed Group | Initiates: Outperform | $21 | $14.01 | +49.89% | 1 | Mar 31, 2026 | |
| LNTH Lantheus Holdings | Maintains: Outperform | $72 → $85 | $76.10 | +11.70% | 8 | Feb 27, 2026 | |
| ESTA Establishment Labs Holdings | Maintains: Outperform | $90 → $100 | $58.37 | +71.32% | 10 | Feb 25, 2026 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $21 → $22 | $18.61 | +18.22% | 3 | Feb 20, 2026 | |
| DXCM DexCom | Maintains: Outperform | $78 → $90 | $62.22 | +44.65% | 4 | Feb 13, 2026 | |
| INSP Inspire Medical Systems | Maintains: Outperform | $130 → $85 | $54.99 | +54.57% | 8 | Feb 12, 2026 | |
| HAE Haemonetics | Maintains: Outperform | $90 → $80 | $56.83 | +40.77% | 17 | Feb 6, 2026 | |
| BSX Boston Scientific | Maintains: Outperform | $140 → $115 | $62.82 | +83.06% | 9 | Feb 5, 2026 | |
| MDXG MiMedx Group | Maintains: Outperform | $12 → $10 | $3.92 | +155.10% | 5 | Dec 17, 2025 | |
| LIVN LivaNova | Maintains: Outperform | $70 → $72 | $63.79 | +12.87% | 10 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $100 → $120 | $93.83 | +27.89% | 4 | Dec 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $85 → $100 | $70.17 | +42.51% | 16 | Dec 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $34.44 | +16.14% | 1 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $110 → $100 | $74.56 | +34.12% | 11 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $310 → $300 | $224.09 | +33.87% | 18 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 → $100 | $81.05 | +23.38% | 10 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $70 → $78 | $75.65 | +3.11% | 10 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $130 → $135 | $117.81 | +14.59% | 9 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $140 → $135 | $102.87 | +31.23% | 6 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $18 | $20.21 | -10.94% | 8 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $98 → $100 | $86.63 | +15.43% | 7 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $12 | $8.85 | +35.59% | 3 | Jul 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $200 → $175 | $112.77 | +55.18% | 10 | Apr 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $6.90 | +479.71% | 1 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $58 | $70.12 | -17.28% | 2 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $14 | $9.19 | +52.34% | 6 | Jun 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $110 → $105 | $70.35 | +49.25% | 6 | May 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $350 → $390 | $452.07 | -13.73% | 6 | Jan 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $63 → $67 | $108.49 | -38.24% | 2 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $175 | $90.89 | +92.54% | 3 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $30 → $25 | $10.50 | +138.10% | 3 | May 13, 2020 |
Minimed Group
Mar 31, 2026
Initiates: Outperform
Price Target: $21
Current: $14.01
Upside: +49.89%
Lantheus Holdings
Feb 27, 2026
Maintains: Outperform
Price Target: $72 → $85
Current: $76.10
Upside: +11.70%
Establishment Labs Holdings
Feb 25, 2026
Maintains: Outperform
Price Target: $90 → $100
Current: $58.37
Upside: +71.32%
Tandem Diabetes Care
Feb 20, 2026
Maintains: Neutral
Price Target: $21 → $22
Current: $18.61
Upside: +18.22%
DexCom
Feb 13, 2026
Maintains: Outperform
Price Target: $78 → $90
Current: $62.22
Upside: +44.65%
Inspire Medical Systems
Feb 12, 2026
Maintains: Outperform
Price Target: $130 → $85
Current: $54.99
Upside: +54.57%
Haemonetics
Feb 6, 2026
Maintains: Outperform
Price Target: $90 → $80
Current: $56.83
Upside: +40.77%
Boston Scientific
Feb 5, 2026
Maintains: Outperform
Price Target: $140 → $115
Current: $62.82
Upside: +83.06%
MiMedx Group
Dec 17, 2025
Maintains: Outperform
Price Target: $12 → $10
Current: $3.92
Upside: +155.10%
LivaNova
Dec 17, 2025
Maintains: Outperform
Price Target: $70 → $72
Current: $63.79
Upside: +12.87%
Dec 17, 2025
Maintains: Outperform
Price Target: $100 → $120
Current: $93.83
Upside: +27.89%
Dec 5, 2025
Maintains: Outperform
Price Target: $85 → $100
Current: $70.17
Upside: +42.51%
Dec 1, 2025
Initiates: Outperform
Price Target: $40
Current: $34.44
Upside: +16.14%
Nov 11, 2025
Maintains: Outperform
Price Target: $110 → $100
Current: $74.56
Upside: +34.12%
Oct 31, 2025
Maintains: Outperform
Price Target: $310 → $300
Current: $224.09
Upside: +33.87%
Oct 31, 2025
Maintains: Outperform
Price Target: $90 → $100
Current: $81.05
Upside: +23.38%
Oct 23, 2025
Downgrades: Neutral
Price Target: $70 → $78
Current: $75.65
Upside: +3.11%
Aug 1, 2025
Maintains: Neutral
Price Target: $130 → $135
Current: $117.81
Upside: +14.59%
Jul 18, 2025
Maintains: Neutral
Price Target: $140 → $135
Current: $102.87
Upside: +31.23%
Jul 16, 2025
Maintains: Neutral
Price Target: $17 → $18
Current: $20.21
Upside: -10.94%
Jul 16, 2025
Maintains: Outperform
Price Target: $98 → $100
Current: $86.63
Upside: +15.43%
Jul 16, 2025
Maintains: Neutral
Price Target: $13 → $12
Current: $8.85
Upside: +35.59%
Apr 16, 2025
Maintains: Outperform
Price Target: $200 → $175
Current: $112.77
Upside: +55.18%
Apr 10, 2025
Initiates: Outperform
Price Target: $40
Current: $6.90
Upside: +479.71%
Mar 6, 2025
Maintains: Buy
Price Target: $54 → $58
Current: $70.12
Upside: -17.28%
Jun 20, 2024
Maintains: Buy
Price Target: $12 → $14
Current: $9.19
Upside: +52.34%
May 1, 2024
Maintains: Buy
Price Target: $110 → $105
Current: $70.35
Upside: +49.25%
Jan 25, 2024
Maintains: Neutral
Price Target: $350 → $390
Current: $452.07
Upside: -13.73%
Aug 3, 2023
Downgrades: Hold
Price Target: $63 → $67
Current: $108.49
Upside: -38.24%
Nov 5, 2021
Maintains: Buy
Price Target: $200 → $175
Current: $90.89
Upside: +92.54%
May 13, 2020
Maintains: Hold
Price Target: $30 → $25
Current: $10.50
Upside: +138.10%